In a significant advancement for Alzheimer’s disease diagnostics, the U.S. Food and Drug Administration (FDA) has greenlighted the first blood test designed to assist in diagnosing Alzheimer’s in adults aged 55 and older who exhibit early signs of cognitive decline.
Alzheimer’s disease, a devastating condition that leads to memory loss and diminished thinking skills, affects more than 55 million people worldwide, and this number is expected to rise sharply as populations age. In the United States alone, over 7 million people are living with the condition, making it a leading cause of death and a major burden on families and Health care systems.
“Today marks another important step in Alzheimer’s disease diagnosis,” said Maria C. Carrillo, Ph.D., Alzheimer’s Association chief science officer and medical affairs lead. “For too long Americans have struggled to get a simple and accurate diagnosis; with today’s action by the FDA we are hopeful it will be easier for more individuals to receive an accurate diagnosis earlier.”
This newly approved test, known as the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, was developed by Fujirebio Diagnostics and offers a less invasive and more accessible alternative to traditional diagnostic methods.
The Lumipulse test measures the levels of two specific proteins in blood plasma: phosphorylated tau protein (pTau217) and β-amyloid 1-42. These proteins are biomarkers associated with the neurodegenerative processes of Alzheimer’s disease. By calculating the ratio of these proteins, the test can detect the presence of amyloid plaques in the brain, a hallmark of Alzheimer’s. This method provides a simpler and more affordable option compared to previous diagnostic procedures like PET scans and spinal taps.
While it does not provide a definitive diagnosis, it serves as a valuable tool in the diagnostic process. A positive result can prompt further in-depth evaluations, while a negative result may help rule out Alzheimer’s as the cause of cognitive symptoms. This approach can facilitate earlier detection and intervention, which is crucial given that Alzheimer’s therapies are most effective in the early stages of the disease.
Moreover, the test’s approval is expected to enhance access to new Alzheimer’s treatments, such as Biogen and Eisai’s Leqembi and Eli Lilly’s Kisunla, which modestly slow disease progression by targeting beta-amyloid. These treatments require confirmation of amyloid plaque presence prior to administration, and the Lumipulse test offers a less invasive means of obtaining this confirmation.
The FDA’s sign-off of the Lumipulse test marks a significant milestone in Alzheimer’s research and patient care. By providing a more accessible diagnostic tool, it opens the door for broader screening and earlier detection, which can lead to timely treatment and better management of the disease. Additionally, it may accelerate the development of new therapies by enabling researchers to identify and monitor patients more effectively.
While the Lumipulse test is not a standalone diagnostic tool, its integration into clinical practice represents a meaningful advancement in the ongoing fight against Alzheimer’s disease.
FDA approves new drug for Alzheimer’s disease
Debunking 8 medical myths about dementia and Alzheimer’s disease
Can Viagra help to boost brain health and prevent Alzheimer’s disease?
A novel new treatment for Alzheimer’s? Xenon gas shows promise, leads to clinical trial
How your personality type may protect you from dementia
Social mobility extends years lived without dementia, Japanese study reveals
Content on this site is for informational purposes only and is not a substitute for professional medical advice. Always check with your qualified healthcare providers with any questions or concerns regarding a medical condition.
